Research Topics
| Douglas E GladstoneSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Partially mismatched transplantation and human leukocyte antigen donor-specific antibodiesDouglas E Gladstone
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD 21287, USA
Biol Blood Marrow Transplant 19:647-52. 2013....- High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863)Douglas E Gladstone
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA
Am J Ther 18:23-30. 2011..The most appropriate candidates for HDC, its duration of benefit, and the potential need for prophylactic preventative immune manipulation after HDC all require further investigation... 
The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemiaDouglas E Gladstone
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Clin Lymphoma Myeloma Leuk 12:132-7. 2012..06). These data suggest that IGHV mutational status has prognostic relevance even in patients with CLL who are defined as poor risk by genomic FISH analysis...- Hematopoietic stem cell transplantation for chronic lymphocytic leukemiaDouglas E Gladstone
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
Curr Opin Oncol 24:176-81. 2012..Now in the era of improved conventional treatment and better prognostication of long-term outcome, a review of autologous and allogeneic HSCT in CLL treatment is warranted... - High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Leuk Lymphoma 52:2076-81. 2011..The 5-year EFS and OS for patients with MCL were 39% and 62%, respectively. This low-toxicity therapeutic approach obviates the need for stem cell products and establishes a platform for future therapies... - Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemiaDouglas E Gladstone
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Leuk Lymphoma 52:1873-81. 2011..001), to receive treatment (p = 0.02), and to have a shorter overall survival (p = 0.13) than the 34 mutated patients. These data suggest that del(13q) conveys an indolent course only in patients with IGHV-mutated CLL... - Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphomaJennifer A Kanakry
Department of Oncology, Johns Hopkins University, Baltimore, Maryland
Biol Blood Marrow Transplant 19:602-6. 2013..AlloBMT may be appropriate in first remission in select high-risk cases... - Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan
Division of Hematologic Malignancies, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Br J Haematol 158:198-207. 2012..In summary, the CLO-CYx4 regimen was well tolerated and had activity in patients with RRAL, especially relapsed ALL. Therefore, CLO-CYx4 can be considered a salvage therapy for adults with RRALs, and warrants further investigations... - Phase 2 study of rituximab-ABVD in classical Hodgkin lymphomaYvette L Kasamon
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Blood 119:4129-32. 2012..Persistence of detectable circulating clonotypic B cells was associated with a greater relapse frequency (P < .05). Rituximab-ABVD and clonotypic B cells warrant additional study in classical Hodgkin lymphoma... - Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaYvette L Kasamon
Johns Hopkins University, Baltimore, MD, USA
Leuk Lymphoma 54:483-90. 2013..Seventeen (81%) received intensification (median 30 days to intensification). Brief, anthracycline-sparing, intensive cyclophosphamide (BASIC) therapy yields durable remissions in poorer-risk BL/atypical BL... - Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemiasJudith E Karp
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland 21287, USA
Clin Cancer Res 18:6723-31. 2012..To extend these findings to the clinical setting, we have conducted a phase I study of cytarabine and SCH 900776... - Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenanceDaniel M Harrison
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Mult Scler 18:202-9. 2012..The long-term benefit of this stabilization followed by conventional therapy has not been explored... 
The role of growth factors in the activity of pharmacological differentiation agentsWilliam H Matsui
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, Maryland 21231, USA
Cell Growth Differ 13:275-83. 2002..These data suggest that many pharmacological differentiating agents require both cell cycle arrest and lineage-specific growth factors for full activity and may explain why these agents have demonstrated only limited clinical efficacy...- Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231 1000, USA
Haematologica 97:1736-42. 2012..6 months...